Page last updated: 2024-12-05

norflurane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norflurane: may replace R 12 as air-conditioning refrigerant; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13129
CHEMBL ID2104432
SCHEMBL ID9499
SCHEMBL ID1789650
MeSH IDM0174110

Synonyms (80)

Synonym
1,1,1,2-tetrafluoroethane or refrigerant gas r 134a
dh9e53k1y8 ,
1,1,1,2-tetrafluoroethane or refrigerant gas r 134a [un3159] [nonflammable liquid]
unii-dh9e53k1y8
ec 212-377-0
norflurano
norfluranum
hfa-134-a
1,1,1,2-tetrafluoroethane
norflurane
refrigerant r134a
r 134a
un3159
hsdb 6756
ccris 7214
norflurane [usan:inn:ban]
hfc 134a
norfluranum [inn-latin]
f 134a
fron 134a
fc 134a
r-134a
1,1,1,2-tetrafluorethan
hcfc 134a
khladon 134a
1,2,2,2-tetrafluoroethane
einecs 212-377-0
arcton 134a
tg 134a
norflurano [inn-spanish]
hfa 134a
811-97-2
norflurane (usan/inn)
D05208
1,1,1,2-tetrafluoroethane, >=99%
ethane, 1,1,1,2-tetrafluoro-
T1476
A840070
1,1,1,2-tetrakis(fluoranyl)ethane
ethane, tetrafluoro-
29759-38-4
hfa-134a
hfc-134a
tetrafluoroethane
FT-0605908
r134a
tetrafluoroethane [vandf]
hfa-134a propellant
norflurane [ii]
norflurane [who-dd]
norflurane [inn]
norflurane [ep monograph]
hfc-134a [mi]
hydrofluorocarbon 134a [inci]
norflurane [usan]
norflurane [hsdb]
norflurane [mart.]
AKOS015853137
solkane 134a
genetron 134a
hydrofluorocarbon 134a
freon 134a
CHEMBL2104432
forane 134a
dymel 134a
suva 134a
SCHEMBL9499
SCHEMBL1789650
cf3ch2f
norfluran
DTXSID1021324
mfcd00066608
1,1,1,2-tetrafluoroethane 100 microg/ml in methanol
norflurane; 1,1,1,2-tetrafluoroethane; hfc 134a
DB13116
1,1,1,2 tetrafluoroethane
Q423029
1,1,1,2-tetrafluoro-ethane
AMY25787
myblxuzjujmvql-uhfffaoysa-n

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation."( Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure.
Alexander, DJ; Borkhataria, D; Duistermaat, E; Emmen, HH; Hoogendijk, EM; Klöpping-Ketelaars, WA; Muijser, H; Ravensberg, JC; Rusch, GM; Schmit, B, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
"The safety, tolerability and systemic pharmacodynamic activity of the salmeterol/HFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design."( Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.
Kirby, SM; Smith, J; Ventresca, GP, 1995
)
0.29
"In healthy volunteers the salmeterol/HFA134a inhaler is at least as safe and well tolerated as the current salmeterol inhaler, and has similar systemic pharmacodynamic activity."( Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.
Kirby, SM; Smith, J; Ventresca, GP, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
"The safety, tolerability and systemic pharmacodynamic activity of the salmeterol/HFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design."( Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.
Kirby, SM; Smith, J; Ventresca, GP, 1995
)
0.29
" Before it can be used, however, particularly as a propellant in an aerosol pharmaceutical formulation whereby the compound is in effect dosed to people, it is important that the safety of this compound is established."( The minimal metabolism of inhaled 1,1,1,2-tetrafluoroethane to trifluoroacetic acid in man as determined by high sensitivity 19F nuclear magnetic resonance spectroscopy of urine samples.
Ismail, I; Mallett, DN; Matthews, C; Monté, SY; Tanner, RJ, 1994
)
0.29
" Pulmonary function and safety measures were assessed after each dosing interval."( Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1998
)
0.3
" HFA134a was rapidly absorbed after inhalation with dose-related blood concentrations which declined rapidly after dosing (t1/2 = 31 min)."( Clinical pharmacology of HFA134a.
Ventresca, GP, 1995
)
0.29
" Unfortunately, for some lesions, the threshold incident light dosage for epidermal injury can be very close to the threshold for permanent removal of the target chromophore, thus precluding the use of higher light dosages."( Active skin cooling in conjunction with laser dermatologic surgery.
Kelly, KM; Majaron, B; Nelson, JS, 2000
)
0.31
"Frost formation following CSC does not usually affect laser dosage delivered for therapy of subsurface targets."( Cryogen spray cooling in laser dermatology: effects of ambient humidity and frost formation.
Aguilar, G; Kimel, S; Lavernia, EJ; Majaron, B; Nelson, JS; Pope, K; Svaasand, LO; Verkruysse, W, 2001
)
0.31
"Spray drying biologics and small-molecule drugs can increase their thermal stability relative to liquid dosage forms and allow for widespread distribution to developing countries without cold chain infrastructure."( Amorphous pullulan trehalose microparticle platform for respiratory delivery.
Barona, D; Carrigy, NB; Finlay, WH; Liu, Y; Melhem, O; Milburn, L; Ordoubadi, M; Ruzycki, CA; Vehring, R; Wang, H, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's25 (26.32)18.2507
2000's37 (38.95)29.6817
2010's28 (29.47)24.3611
2020's5 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.09 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index76.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (15.53%)5.53%
Reviews5 (4.85%)6.00%
Case Studies4 (3.88%)4.05%
Observational0 (0.00%)0.25%
Other78 (75.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover Phase 1/2a Study Testing Safety/Efficacy of Advair HFA (Salmeterol, Fluticasone) in Resting & Exercising Healthy & High Altitude Pulmonary Edema (HAPE) Predisposed Subjects [NCT06040268]Phase 1/Phase 260 participants (Anticipated)Interventional2023-12-12Recruiting
The Effect of Alcoholic-carrier Solutions Within-devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers [NCT02264145]Phase 120 participants (Actual)Interventional1998-11-30Completed
A Single-Dose, Double Blind, Crossover Trial to Determinate the Comparability of Ipratropium Bromide HFA-134a Inhalation Aerosol to the Market Standard, Atrovent® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT02260011]Phase 241 participants (Actual)Interventional2000-10-31Completed
A Single Dose Two-way Cross-over Study in Healthy Participants to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152a and HFA-134a [NCT05791565]Phase 128 participants (Actual)Interventional2023-04-03Completed
A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250 [NCT00633217]Phase 4247 participants (Actual)Interventional2008-03-31Completed
A 12-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Mild to Moderate Persistent Asthma [NCT00862264]Phase 3286 participants (Actual)Interventional2004-08-31Completed
The Effect of HFA-beclomethasone Dipropionate on Static Lung Volumes in COPD [NCT00238082]20 participants (Actual)Interventional1999-11-30Terminated
Vapocoolant Spray as a Novel Local Anesthetic for Cutaneous Abscess Incision and Drainage [NCT01673061]Phase 421 participants (Actual)Interventional2012-08-31Terminated(stopped due to Vapocoolant not effective controlling pain compared with Lidocaine.)
An Open-Label, Crossover, Pharmacokinetic Trial to Determine the Comparability of 84 µg Ipratropium Bromide HFA-134a Inhalation Aerosol to 84 µg ATROVENT® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT02236169]Phase 230 participants (Actual)Interventional2000-10-31Completed
Open-label, Randomised, Controlled, 2-way Cross-over Study to Assess the Effect of Multiple Doses of the New HFA-152a Propellant Versus the Marketed HFA-134a Propellant on Mucociliary Clearance in Healthy Volunteers [NCT05875025]Phase 120 participants (Actual)Interventional2023-06-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00633217 (3) [back to overview]Mean Change From Baseline in AM Pre-dose FEV1
NCT00633217 (3) [back to overview]Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug
NCT00633217 (3) [back to overview]Mean Change From Baseline in Peak Expiratory Flow

Mean Change From Baseline in AM Pre-dose FEV1

Change from baseline was calculated as the value at Endpoint minus the baseline value. AM pre-dose FEV1, which is assessed using spirometry, is the maximum amount of air you can forcefully exhale in one second prior to taking the morning dose of study drug. Endpoint was defined as the last scheduled observation for AM pre-dose FEV1 during the 12-week treatment period. (NCT00633217)
Timeframe: Measurement of FEV1 prior to study drug administration; Baseline through Week 12

InterventionmL (Mean)
HFA MDI 230/42 mcg and Matching DISKUS Placebo74
DISKUS 250/50 mcg and Matching HFA MDI Placebo77

[back to top]

Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug

The primary efficacy analysis was mean change from baseline in 2-hour post-dose FEV1 compared between the two treatment groups at Endpoint. Change from baseline was calculated as the value at Endpoint minus the baseline value. FEV1, which is assessed using spirometry, is the maximal amount of air you can forcefully exhale in one second. Endpoint was defined as the last scheduled observation for 2 hour post-dose FEV1 during the 12-week treatment period. (NCT00633217)
Timeframe: 2 hours after administration of blinded study drug; Baseline through Week 12

Interventionmilliliters (mL) (Mean)
HFA MDI 230/42 mcg and Matching DISKUS Placebo155
DISKUS 250/50 mcg and Matching HFA MDI Placebo150

[back to top]

Mean Change From Baseline in Peak Expiratory Flow

The peak expiratory flow is a measure of the amount of air that can be pushed through the airways in a single rapid exhalation. This is measured by a peak flow meter which is a hand held device. Change from baseline was calculated as the average value over Weeks 1-12 minus the baseline value. (NCT00633217)
Timeframe: Baseline through Week 12

InterventionLiters/minute (L/min) (Mean)
HFA MDI 230/42 mcg and Matching DISKUS Placebo21.8
DISKUS 250/50 mcg and Matching HFA MDI Placebo18.7

[back to top]